|Videos|August 11, 2021

The Unpredictable Factors of the 2021-22 Flu Season

A look at the COVID-19 driven factors for this upcoming influenza season, from reopening classrooms to reduced mutation chances.

Following a minimal influenza season amid rampant COVID-19 outbreak during 2020-21, US experts are beginning to speculate the risk of a worse 2021-22 flu season.

As many are indicating, though, the factors influencing flu outbreak risk are varied—and sometimes linked to COVID-19 response.

In the next segment of an interview with Contagion, Jason C. Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, Clinical Professor at Temple University School of Pharmacy, discussed the unknown expectations of the upcoming flu season. One major influence, Gallagher noted, is the evolving strategies of classroom settings.

“Unlike for COVID, kids are what spread influenza, and those kids were not together in the same way,” Gallagher said. “Some of them were remote learning, others were together in the classrooms with masks or social distancing.”

Gallagher also noted that parental anxiety surrounding COVID-19 may influence likelihood of flu spread among children this year. He expressed overall concern for what a quieter 2020-21 season may indicate for future seasons as well.

“I also am curious as to whether our vaccine will be matched well against the strains that emerge,” he said. “I don’t think we have a reason to think it won’t, just because there’s been less influenza overall and less chance for it to mutate.”

Again, how such evolving factors and responses to another respiratory virus outbreak influence the flu season are difficult to project.

“Those kind of things are all pretty hard to quantify but all come into this equation,” Gallagher said. “Coming into this year, it’s obviously going to be different.”


Related to this article

REMAP-CAP and the Tamiflu “Pre-Release”: A Set-Up for Disaster
Preliminary REMAP-CAP data suggesting oseltamivir may increase mortality in critically ill ICU influenza patients has sparked polarized reactions, but clinicians should await the full peer-reviewed manuscript before drawing broad conclusions, since the signal comes from a narrow, severely ill population and may reflect a therapeutic window effect rather than a blanket lack of efficacy.
GSK's mRNA Influenza Vaccine Moves to Phase 3 Trial
GSK will advance its investigational mRNA seasonal flu vaccine candidate, which targets both hemagglutinin and neuraminidase, into a phase 3 trial in September 2026 after the shot outperformed licensed flu vaccines in a phase 2 study.
How The Food Safety Surveillance Infrastructure Works in the US
In the first episode of our news series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates, and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
New Diagnositics for Legionella Pneumonia May Streamline Care Continuum
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.